IPO Databook: BlossomHill Therapeutics (BLSM US) - Aug 2026

107 Views05 Aug 2026 10:16

SUMMARY

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer treatment using a chemistry-based approach.
BH-30643 is in global Phase 1/2 for EGFR-mutant NSCLC, and BH-30236 is in Phase 1 for R/R AML and HR-MDS.
The independent registered public accounting firm included a "going concern" explanatory paragraph in its report.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream